Re Marketing Agreement

Dechra Pharmaceuticals PLC
11 December 2003


Issued by Citigate Dewe Rogerson, Birmingham
Date: Thursday 11 December 2003
                                                               Embargoed: 7.00am

   Dechra secures European Partner Janssen Animal Health, for its veterinary
                     products Vetoryl(R) and Felimazole(R)

Dechra Pharmaceuticals PLC ('Dechra' or 'the Group') has signed a European
marketing agreement with Janssen Animal Health, a division of Johnson & Johnson.

The partnership, which will run for an initial period of five years, gives
Janssen Animal Health the marketing and distribution rights in mainland Europe
to Dechra's own developed products, Vetoryl and Felimazole.

Dechra, assisted by Janssen Animal Health, will be seeking regulatory approvals
through the European mutual recognition process. Target dates for launch are
quarter one year ending June 2005 for Felimazole and quarter three of the same
year for Vetoryl.

Dechra will retain all intellectual property rights and the products will be
manufactured at Dales Pharmaceuticals, the manufacturing arm of Dechra.

Ian Page, Chief Executive, Dechra commented:

'The marketing partnership with Janssen Animal Health is a significant milestone
in our strategy to develop and license our own branded veterinary pharmaceutical
portfolio in key international markets.'

Ed Torr, Development Director responsible for the Group's product licensing and
development programme added:

'The agreement with Janssen Animal Health secures an experienced marketing
partner whose knowledge of the European markets will allow the launch of these
products in the selected territories more quickly and cost effectively than we
could have done independently.'

Pierre Scarceriaux, General Manager, Janssen Animal Health Worldwide Business
commented:

'The agreement with Arnolds adds on two exciting products to the portfolio of
Janssen Animal Health and illustrates that our company is recognized as a
trustworthy and dedicated partner'.

Enquiries:
Dechra(R) Pharmaceuticals PLC                                Citigate Dewe Rogerson
Ian Page, Chief Executive     Ed Torr, Development Director  Fiona Tooley/Katie Dale
[e-mail]        [e-mail]          Tel:[phone]
Tel: [phone]      Tel: [phone]       Mobile [phone] (FMT)
                                                             [e-mail]

Simon Evans, Group Finance Director
[e-mail]
Tel: [phone]

Janssen Animal Health B.V.B.A.
Pierre Scarceriaux, General Manager
[e-mail]
Tel: [phone]

Guy Braem, Director Business Development
[e-mail]
Tel: [phone]

Editors Notes

Vetoryl
Vetoryl was launched into the UK market in late 2001 and has already achieved
annualised sales exceeding £1,000,000. Developed and marketed by Arnolds
Veterinary Products, Vetoryl is currently available in two dosage forms, 60mg
and 120mg capsules, with a 30mg capsule under development.

Vetoryl is the only licensed product in the UK for the treatment of Cushings
Disease in dogs (pituitary and adrenal tumours). The disease is one of the most
common endocrine disorders diagnosed in dogs affecting all breeds primarily over
the age of 7 years.

Trilostane, the chemical active in Vetoryl selectively blocks glucocorticoid
synthesis, reducing serum cortisol levels. Research has shown that it is
effective in reducing the symptoms of Cushings Disease in over 90% of dogs
treated.

Felimazole
Felimazole was launched into the UK market in April 2002, it's license being
extended for lifelong treatment of Feline Hyperthyroidism in December 2002.
Annualised sales in this period are approaching £500,000. Felimazole is the only
licensed product on the market and was developed in-house by Arnolds Veterinary
Products. It is currently available as a small, 5mg, palatable sugar coated
tablet for cats. Developments to extend the range are in progress.

Feline Hyperthyroidism is the most commonly diagnosed endocrine disorder in
cats, in over 70% of cases the thyroid gland is enlarged. Clinical signs are
hyperactivity, weight loss, increased heart rate and anxiety. The disease
affects cats mainly over the age of 10 years.

Methimazole, the chemical active in Felimazole is effective in reducing the high
serum thyroid hormone concentrations, thus enabling the cat to stabilise its
thyroid hormone production and alleviate the clinical symptoms of the disease.

About Dechra Pharmaceuticals PLC
www.dechra.com
Dechra Pharmaceuticals are specialists in the UK and international veterinary
and animal healthcare markets. Key to the Group's strategy is the worldwide
development of its veterinary pharmaceuticals portfolio.

Quoted on the London Stock Exchange (under pharmaceuticals and biotech: Reuters:
DPH.L), the business has four businesses: National Veterinary Services ('NVS'),
Arnolds Veterinary Products ('Arnolds'), Dales Pharmaceuticals Limited
('Dales'), NationWide Laboratories/Cambridge Specialist Laboratory Services.

Arnolds Veterinary Products Limited
www.arnolds.co.uk
Arnolds is one of the most well respected and recognised brand names in the UK
veterinary market, and holds leading positions in several specialist therapy
areas including endocrinology, local anaesthesia and equine anti-inflammatory
treatments. Its companion animal product development pipeline is focused on
areas in cardiology, endocrinology, oncology and respiratory diseases.

About Janssen, a division of Johnson & Johnson
www.janssenanimalhealth.com
Janssen Animal Health is a business franchise within Janssen Pharmaceutica,
itself a division of Johnson & Johnson.

In most European countries, as well as South Africa, Janssen's products are
available through the Janssen Animal Health marketing organisation. Elsewhere,
they are distributed by approved veterinary pharmaceutical companies.

Janssen Animal Health is renown for products coming from it's own research such
as antiparasitic and antimycotic products and is also a well respected partner
for other pharmaceutical companies for products in specialized fields.



                      This information is provided by RNS
            The company news service from the London Stock Exchange